| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Can A Genentech Upgrade Fix Its Woes?
Posted on 06/09/2007 06:19:23 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
This morning shares of Genentech (DNA) are trading up 1.3% at just under $76.00 after a Deutsche Bank upgrade on the stock. Shares closed at $74.90 yesterday and even traded as low as $74.32 intraday. Both levels marked lows for the last 52-weeks, but this is actually a critical juncture because the stock broke a two-year low since their was no 'wow-effect' at all this year from the ASCO conference last weekend.
The Deutsche Bank upgrade this morning from a 'Hold' to 'Buy' is based on discount valuations and upon treatments for colon cancer, MS, and lupus. The 12-month target is somewhat in-line with many of the older 'buy' targets from Wall Street and is listed as $95.00.
Continue article at 247WallSt.com
RELATED READING:
- The outspoken Genentech CEO, Arthur Levinson
BioHealth Investor.com
______________________
24/7 Wall St.
This morning shares of Genentech (DNA) are trading up 1.3% at just under $76.00 after a Deutsche Bank upgrade on the stock. Shares closed at $74.90 yesterday and even traded as low as $74.32 intraday. Both levels marked lows for the last 52-weeks, but this is actually a critical juncture because the stock broke a two-year low since their was no 'wow-effect' at all this year from the ASCO conference last weekend.The Deutsche Bank upgrade this morning from a 'Hold' to 'Buy' is based on discount valuations and upon treatments for colon cancer, MS, and lupus. The 12-month target is somewhat in-line with many of the older 'buy' targets from Wall Street and is listed as $95.00.
Continue article at 247WallSt.com
RELATED READING:
- The outspoken Genentech CEO, Arthur Levinson
BioHealth Investor.com
______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Millionaire Now! by Larry Nusbaum
- Ludwig von Mises Institute
- Credit Bloggers
- Don't Mess With Taxes
- Invest2Success
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Fri Jul 18, 2008 08:23AM
U.S. stock futures rebound on Citigroup results"S&a [read more]
U.S. stock futures rebound on Citigroup results"S&a [read more]
<< My Home | TheMoneyBlogs Home